摘要
Abstract
Objective To explore the clinical application value of circulating tumor DNA(ctDNA)in prognostic evaluation of esophageal malignancies.Methods Pubmed,Cochrane Library,Embase and Web of Science databases were used to search articles discussing the clinical application value of ctDNA in the prognosis assessment of esophageal malignancies from the establishment of the database to November 24,2022.Two researchers independently searched the database,screened the literature,extracted and analyzed the data,analyzed the risk of bias in the included literature,extracted the risk ratio(hr)of disease-free survival(DFS)and overall survival(OS),and used Revman 5.3 for statistical analysis.Chi-square test was used to calculate the heterogeneity among the com-bined results.Results A total of 321 patients were included in this study,among which 8 studies were included in the PFS meta-anal-ysis of ctDNA prediction of esophageal malignancies.he heterogeneity of progression-free survival(PFS)in patients with esophageal malignancies was low(I2=28％,P＞0.05),so the fixed-effect model was used(HR=4.14,95％CI:2.65～6.47,P＜0.05).The results showed that ctDNA-positive patients were associated with poor PFS.In the meta-analysis of ctDNA's prediction of overall sur-vival(OS)in patients with esophageal malignancies,a total of 4 studies were included,with low heterogeneity(I2=15％,P＞0.05).Using a fixed-effect model,CtDNA-positive patients had worse prognosis than ctDNA-negative patients with OS(HR=4.71,95％CI:2.78～7.97,P＜0.05).Conclusions Tumor-associated ctDNA detection is expected to become an auxiliary prognostic measure for patients with esophageal malignancies.关键词
食管恶性肿瘤/ctDNA/Meta分析Key words
esophageal malignancy/ctDNA/Meta-analysis分类
医药卫生
